BioNexus Gene Lab Corp (BGLC)
NASDAQ:BGLC
US Market
Holding BGLC?
Track your performance easily

BioNexus Gene Lab Corp (BGLC) Income Statement

53 Followers

BioNexus Gene Lab Corp Income Statement

Last quarter (Q ), BioNexus Gene Lab Corp's total revenue was $1.97M, a decrease of -16.94% from the same quarter last year. In Q, BioNexus Gene Lab Corp's net income was $199.10K. See BioNexus Gene Lab Corp’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 9.48M$ 9.77M$ 10.93M$ 13.36M$ 11.39M$ 126.95K
Cost of Revenue
$ 8.13M$ 8.44M$ 9.67M$ 11.10M$ 9.67M$ 71.07K
Gross Profit
$ 1.35M$ 1.33M$ 1.26M$ 2.27M$ 1.72M$ 55.89K
Operating Expense
$ 5.29M$ 4.41M$ 11.40M$ 12.37M$ 11.00M$ 356.64K
Operating Income
$ -2.62M$ -2.59M$ -291.18K$ 1.06M$ 1.27M$ -300.75K
Net Non Operating Interest Income Expense
$ -4.66K$ -13.93K----
Other Income Expense
$ -1.33M$ -486.04K$ -179.28K$ -66.49K$ -886.94K$ -25.05K
Pretax Income
$ -2.64M$ -2.61M$ -303.66K$ 1.04M$ 1.42M$ -265.83K
Tax Provision
$ 136.08K$ 21.53K$ 52.31K$ 291.28K$ 168.41K$ -20.28K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -2.77M$ -2.63M$ -355.97K$ 751.57K$ 1.09M$ -216.31K
Basic EPS
$ -0.16$ -0.19--$ 0.12-
Diluted EPS
$ -0.16$ -0.19--$ 0.12-
Basic Average Shares
----$ 8.58M$ 7.20M
Diluted Average Shares
----$ 8.58M$ 7.20M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 13.42M$ 12.85M$ 21.07M$ 23.47M$ 20.67M$ 427.71K
Net Income From Continuing And Discontinued Operation
$ -2.77M$ -2.63M$ -156.97K$ 751.57K$ 1.09M$ -216.31K
Normalized Income
$ -2.10M-$ -348.17K$ 805.04K--
Interest Expense
------
EBIT
$ -2.61M$ -2.59M$ -291.18K$ 1.06M$ 1.27M$ -265.83K
EBITDA
$ -2.50M$ -2.49M$ -185.76K$ 1.16M$ 1.38M$ -212.50K
Currency in USD

BioNexus Gene Lab Corp Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis